Overview

Pneumococcal Vaccine Market is poised to value USD 10722 million by 2028 end at a CAGR of 4.6% during the forecast period 2022 to 2028.

Infections include middle ear infections, blood infections, pneumonia, and bacterial meningitis are all part of the widespread and frequently mild pneumococcal illness. The illness, however, occasionally brings about serious and grave health issues. The causal agent of pneumococcal pneumonia, streptococcus pneumonia, is protected against by pneumococcal vaccinations. Conjugate vaccination and polysaccharide vaccine are the two forms of vaccine that are offered. The intramuscular method is used to give pneumococcal vaccinations. While polysaccharide vaccinations are beneficial in healthy adults, conjugate vaccines are given to infants. To avoid infection from the streptococcus pneumoniae bacteria, pneumococcal vaccination is utilised. There are two different pneumococcal vaccines: the polysaccharide vaccine and the conjugate vaccine. For individuals of various ages experiencing various infections and past disorders, there are distinct directions and dosages. One of the key factors propelling the growth of the pneumococcal vaccine market is the rise in the number of pneumonia cases around the world. The increased demand for specialised medications to treat disease-related consequences like breathing problems and the increase in funding provided to researchers to create novel interventions or treatments both contribute to the market's rapid expansion. The market is also impacted by an increase in the launch of innovative pneumococcal vaccines, rising government spending, and increased health-awareness initiatives. Additionally, the market for pneumococcal vaccines is positively impacted by technological advancement, an increase in healthcare spending, population expansion, and special regulatory designation. The market for pneumococcal vaccinations is anticipated to have an increase in overall revenue during the forecast period as a consequence of rising efforts by numerous nations to offer such vaccines in conjunction with funding programmes.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Pneumococcal Vaccine Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis,market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of the market.

According to the research study conducted by FutureWise research analysts, the Pneumococcal Vaccine Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the Pneumococcal Vaccine Market along with the growth opportunities present across this business vertical.

Major players included in the Pneumococcal Vaccine Market are :

• Merck & Co., Inc.
• Pfizer Inc.
• GlaxoSmithKline plc.
• Sanofi Pasteur
• China National Biotec Group
• Astellas Pharma Inc
• Serum Institute of India Pvt. Ltd.
• GAVI
• Panacea Biotec
• Aurobindo Pharma
(Note: The list of the major players will be updated with the latest market scenario and trends)

Pneumococcal Vaccine Market Segmentation:

By Vaccine Type
• Penumococcal Conjugate Vaccine
• Pneumococcal Polysaccharide Vaccine
By Dosage
• Single Dose Vial
• Pre-Filled Syringe
By End-User
• Children aged 2 to 10
• Adulst aged 10  to 64
• Geriatric aged more than 65
By Region
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Competitive Landscape:

• Tier 1 players- established companies in the market with a major market share  
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants

FutureWise Key Takeaways:

• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

Objectives of the Study:

• To provide with an exhaustive analysis on the Pneumococcal Vaccine Market By Vaccine Type, By Dosage, By End-User and by region
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa
• To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

Flexible Delivery Model:

• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customization services offered are free of charge with purchase of any license of the report.
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents

1. Market Introduction
   1.1. Objectives of the Study 
   1.2. Market Definition 
   1.3. Market Scope 
        1.3.1. Years Considered for the Study
        1.3.2. Market Covered
   1.4. Currency 
   1.5. Limitations 
   1.6. Stakeholders 

2. Research Methodology 
   2.1. Research Data 
        2.1.1. Secondary Data
               2.1.1.1. Key Data from Secondary Sources
        2.1.2. Primary Data
               2.1.2.1. Key Data from Primary Sources
   2.2. Market Size Estimation 
   2.3. Market Breakdown and Data Triangulation 
   2.4. Assumptions for the Study  

3. Executive Summary
   3.1. Market Outlook
   3.2. Segment Outlook
   3.3. Competitive Insights

4. Pneumococcal Vaccine Market Variables, Trends & Scope
   4.1. Market Lineage Outlook
   4.2. Penetration and Growth Prospect Mapping
   4.3. Industry Value Chain Analysis
   4.4. Cost Analysis Breakdown
   4.5. Technology Overview
   4.6. Regulatory Framework
        4.6.1. Reimbursement Framework
        4.6.2. Standards and Compliances

5. Market Overview
   5.1. Market Dynamics
        5.1.1. Market Driver Analysis
               5.1.1.1. Increasing focus of Pneumococcal Vaccine Market Companies on Brand Protection
               5.1.1.2. Untapped Opportunities in Emerging Regions
        5.1.2. Market Restraint Analysis
               5.1.2.1. High Cost Associated with Implementation of Predictive Analysis
        5.1.3. Industry Challenges
               5.1.3.1. Presence of Ambiguous Regulatory Framework

6. Pneumococcal Vaccine Market Analysis Tools
   6.1. Industry Analysis - Porter’s
        6.1.1. Supplier Power
        6.1.2. Buyer Power
        6.1.3. Substitution Threat
        6.1.4. Threat from New Entrants
        6.1.5. Competitive Rivalry
   6.2. Pestel Analysis
        6.2.1. Political Landscape
        6.2.2. Environmental Landscape
        6.2.3. Social Landscape
        6.2.4. Technology Landscape
        6.2.5. Legal Landscape
   6.3. Major Deals And Strategic Alliances Analysis
        6.3.1. Joint Ventures
        6.3.2. Mergers and Acquisitions
        6.3.3. Licensing and Partnership
        6.3.4. Technology Collaborations
        6.3.5. Strategic Divestments
   6.4. Market Entry Strategies
   6.5. Case Studies

7. Pneumococcal Vaccine Market, By Vaccine Type Historical Analysis and Forecast 2022-2028 (USD Million)
   7.1. Penumococcal Conjugate Vaccine
   7.2. Pneumococcal Polysaccharide Vaccine

8. Pneumococcal Vaccine Market, By Dosage Historical Analysis and Forecast 2022-2028 (USD Million)  
   8.1. Single Dose Vial
   8.2. Pre-Filled Syringe

9. Pneumococcal Vaccine Market, By End-User Historical Analysis and Forecast 2022-2028 (USD Million)  
   9.1. Children aged 2 to 10
   9.2. Adulst aged 10  to 64
   9.3. Geriatric aged more than 65

10. North America Pneumococcal Vaccine Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    10.1. Introduction
    10.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          10.2.1. U.S.A
          10.2.2. Canada
          10.2.3. Mexico
    10.3. Market Size (USD Million) Forecast for North America 2022-2028

11. Latin America Pneumococcal Vaccine Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    11.1. Introduction
    11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          11.2.1. Brazil
          11.2.2. Venezuela
          11.2.3. Argentina
          11.2.4. Rest of Latin America
    11.3. Market Size (USD Million) Forecast for Latin America 2022-2028

12. Europe Pneumococcal Vaccine Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    12.1. Introduction
    12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          12.2.1. Germany
          12.2.2. U.K         
          12.2.3. France
          12.2.4. Italy
          12.2.5. Spain
          12.2.6. Russia
          12.2.7. Poland
          12.2.8. Rest of Europe
    12.3. Market Size (USD Million) Forecast for Europe 2022-2028

13. Asia Pacific Pneumococcal Vaccine Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    13.1. Introduction
    13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          13.2.1. Japan
          13.2.2. China
          13.2.3. India
          13.2.4. Australia and New Zealand
          13.2.5. ASEAN
          13.2.6. Rest of Asia Pacific
    13.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028  

14. Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    14.1. Introduction
    14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          14.2.1. GCC
          14.2.2. Israel
          14.2.3. South Africa
          14.2.4. Rest of MEA
    14.3. Market Size (USD Million) Forecast for MEA 2022-2028

15. Market Share Analysis and Competitive Landscape   
    15.1. Global Landscape - Key Players, Revenue and Presence
    15.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
    15.3. Global Emerging Companies
    15.4. North America - Market Share Analysis and Key Regional Players
    15.5. Europe - Market Share Analysis and Key Regional Players
    15.6. Asia Pacific - Market Share Analysis and Key Regional Players
    15.7. Global Key Player - Growth Matrix

16. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    16.1. Merck & Co., Inc.
          16.1.1. Company Overview
          16.1.2. Product Portfolio
          16.1.3. SWOT Analysis
          16.1.4. Financial Overview
          16.1.5. Strategic Overview
    16.2. Pfizer Inc.
          16.2.1. Company Overview
          16.2.2. Product Portfolio
          16.2.3. SWOT Analysis
          16.2.4. Financial Overview
          16.2.5. Strategic Overview 
    16.3. GlaxoSmithKline plc.
          16.3.1. Company Overview
          16.3.2. Product Portfolio
          16.3.3. SWOT Analysis
          16.3.4. Financial Overview
          16.3.5. Strategic Overview
    16.4. Sanofi Pasteur
          16.4.1. Company Overview
          16.4.2. Product Portfolio
          16.4.3. SWOT Analysis
          16.4.4. Financial Overview
          16.4.5. Strategic Overview
    16.5. China National Biotec Group
          16.5.1. Company Overview
          16.5.2. Product Portfolio
          16.5.3. SWOT Analysis
          16.5.4. Financial Overview
          16.5.5. Strategic Overview          
    16.6. Astellas Pharma Inc
          16.6.1. Company Overview
          16.6.2. Product Portfolio
          16.6.3. SWOT Analysis
          16.6.4. Financial Overview
          16.6.5. Strategic Overview     
    16.7. Serum Institute of India Pvt. Ltd.
          16.7.1. Company Overview
          16.7.2. Product Portfolio
          16.7.3. SWOT Analysis
          16.7.4. Financial Overview
          16.7.5. Strategic Overview
    16.8. GAVI
          16.8.1. Company Overview
          16.8.2. Product Portfolio
          16.8.3. SWOT Analysis
          16.8.4. Financial Overview
          16.8.5. Strategic Overview 
    16.9. Panacea Biotec
          16.9.1. Company Overview
          16.9.2. Product Portfolio
          16.9.3. SWOT Analysis
          16.9.4. Financial Overview
          16.9.5. Strategic Overview
    16.10.Aurobindo Pharma
          16.10.1. Company Overview
          16.10.2. Product Portfolio
          16.10.3. SWOT Analysis
          16.10.4. Financial Overview
          16.10.5. Strategic Overview

17. Pre and Post COVID-19 Impact
    17.1. Positive influence on the healthcare industry
    17.2. The financial disruption of the manufacturing sector
    17.3. Impact of COVID-19 on emerging companies
    17.4. Significant mandates in the regulations initiated by healthcare administrations
    17.5. The overall economic slowdown of the developing and developed nations

18. FutureWise SME Key Takeaway Points for Client

Tables

Figures